Selected research
Industry Research
CXCR4 Antagonists Industry Research Report 2026
Market perspective
The global CXCR4 Antagonists market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the CXCR4 Antagonists market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the CXCR4 Antagonists market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the CXCR4 Antagonists market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of CXCR4 Antagonists include Sanofi, Merck, Roche, Eli Lilly, X4 Pharmaceuticals, Upsher-Smith Laboratories, Harmonic Pharma, GlycoMimetics and BioLineRx and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global CXCR4 Antagonists market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to CXCR4 Antagonists.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
CXCR4 Antagonists Market by Company
Sanofi
Merck
Roche
Eli Lilly
X4 Pharmaceuticals
Upsher-Smith Laboratories
Harmonic Pharma
GlycoMimetics
BioLineRx
Biokine Therapeutics
CXCR4 Antagonists Segment by Type
USL311
Balixafortide (POL6326)
GMI-1359
BL-8040
Plerixafor (AMD3100)
Others
CXCR4 Antagonists Segment by Application
Chronic Inflammatory Diseases
HIV
Cancer
CXCR4 Antagonists Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CXCR4 Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CXCR4 Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CXCR4 Antagonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of CXCR4 Antagonists companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- USL311
- Balixafortide (POL6326)
- GMI-1359
- BL-8040
- Plerixafor (AMD3100)
- Others
Applications
- Chronic Inflammatory Diseases
- HIV
- Cancer
Companies covered
- Sanofi
- Merck
- Roche
- Eli Lilly
- X4 Pharmaceuticals
- Upsher-Smith Laboratories
- Harmonic Pharma
- GlycoMimetics
- BioLineRx
- Biokine Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 CXCR4 Antagonists by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 USL311
- 2.2.3 Balixafortide (POL6326)
- 2.2.4 GMI-1359
- 2.2.5 BL-8040
- 2.2.6 Plerixafor (AMD3100)
- 2.2.7 Others
- 2.3 CXCR4 Antagonists by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Chronic Inflammatory Diseases
- 2.3.3 HIV
- 2.3.4 Cancer
- 2.4 Assumptions and Limitations
3 CXCR4 Antagonists Breakdown Data by Type
- 3.1 Global CXCR4 Antagonists Historic Market Size by Type (2021-2026)
- 3.2 Global CXCR4 Antagonists Forecasted Market Size by Type (2027-2032)
4 CXCR4 Antagonists Breakdown Data by Application
- 4.1 Global CXCR4 Antagonists Historic Market Size by Application (2021-2026)
- 4.2 Global CXCR4 Antagonists Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global CXCR4 Antagonists Market Perspective (2021-2032)
- 5.2 Global CXCR4 Antagonists Growth Trends by Region
- 5.2.1 Global CXCR4 Antagonists Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 CXCR4 Antagonists Historic Market Size by Region (2021-2026)
- 5.2.3 CXCR4 Antagonists Forecasted Market Size by Region (2027-2032)
- 5.3 CXCR4 Antagonists Market Dynamics
- 5.3.1 CXCR4 Antagonists Industry Trends
- 5.3.2 CXCR4 Antagonists Market Drivers
- 5.3.3 CXCR4 Antagonists Market Challenges
- 5.3.4 CXCR4 Antagonists Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top CXCR4 Antagonists Players by Revenue
- 6.1.1 Global Top CXCR4 Antagonists Players by Revenue (2021-2026)
- 6.1.2 Global CXCR4 Antagonists Revenue Market Share by Players (2021-2026)
- 6.2 Global CXCR4 Antagonists Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of CXCR4 Antagonists Head Office and Area Served
- 6.4 Global CXCR4 Antagonists Players, Product Type & Application
- 6.5 Global CXCR4 Antagonists Manufacturers Established Date
- 6.6 Global CXCR4 Antagonists Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America CXCR4 Antagonists Market Size (2021-2032)
- 7.2 North America CXCR4 Antagonists Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America CXCR4 Antagonists Market Size by Country (2021-2026)
- 7.4 North America CXCR4 Antagonists Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe CXCR4 Antagonists Market Size (2021-2032)
- 8.2 Europe CXCR4 Antagonists Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe CXCR4 Antagonists Market Size by Country (2021-2026)
- 8.4 Europe CXCR4 Antagonists Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific CXCR4 Antagonists Market Size (2021-2032)
- 9.2 Asia-Pacific CXCR4 Antagonists Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific CXCR4 Antagonists Market Size by Country (2021-2026)
- 9.4 Asia-Pacific CXCR4 Antagonists Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America CXCR4 Antagonists Market Size (2021-2032)
- 10.2 South America CXCR4 Antagonists Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America CXCR4 Antagonists Market Size by Country (2021-2026)
- 10.4 South America CXCR4 Antagonists Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa CXCR4 Antagonists Market Size (2021-2032)
- 11.2 Middle East & Africa CXCR4 Antagonists Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa CXCR4 Antagonists Market Size by Country (2021-2026)
- 11.4 Middle East & Africa CXCR4 Antagonists Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in CXCR4 Antagonists Business (2021-2026)
- 12.1.4 Sanofi CXCR4 Antagonists Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Merck
- 12.2.1 Merck Company Information
- 12.2.2 Merck Business Overview
- 12.2.3 Merck Revenue in CXCR4 Antagonists Business (2021-2026)
- 12.2.4 Merck CXCR4 Antagonists Product Portfolio
- 12.2.5 Merck Recent Developments
- 12.3 Roche
- 12.3.1 Roche Company Information
- 12.3.2 Roche Business Overview
- 12.3.3 Roche Revenue in CXCR4 Antagonists Business (2021-2026)
- 12.3.4 Roche CXCR4 Antagonists Product Portfolio
- 12.3.5 Roche Recent Developments
- 12.4 Eli Lilly
- 12.4.1 Eli Lilly Company Information
- 12.4.2 Eli Lilly Business Overview
- 12.4.3 Eli Lilly Revenue in CXCR4 Antagonists Business (2021-2026)
- 12.4.4 Eli Lilly CXCR4 Antagonists Product Portfolio
- 12.4.5 Eli Lilly Recent Developments
- 12.5 X4 Pharmaceuticals
- 12.5.1 X4 Pharmaceuticals Company Information
- 12.5.2 X4 Pharmaceuticals Business Overview
- 12.5.3 X4 Pharmaceuticals Revenue in CXCR4 Antagonists Business (2021-2026)
- 12.5.4 X4 Pharmaceuticals CXCR4 Antagonists Product Portfolio
- 12.5.5 X4 Pharmaceuticals Recent Developments
- 12.6 Upsher-Smith Laboratories
- 12.6.1 Upsher-Smith Laboratories Company Information
- 12.6.2 Upsher-Smith Laboratories Business Overview
- 12.6.3 Upsher-Smith Laboratories Revenue in CXCR4 Antagonists Business (2021-2026)
- 12.6.4 Upsher-Smith Laboratories CXCR4 Antagonists Product Portfolio
- 12.6.5 Upsher-Smith Laboratories Recent Developments
- 12.7 Harmonic Pharma
- 12.7.1 Harmonic Pharma Company Information
- 12.7.2 Harmonic Pharma Business Overview
- 12.7.3 Harmonic Pharma Revenue in CXCR4 Antagonists Business (2021-2026)
- 12.7.4 Harmonic Pharma CXCR4 Antagonists Product Portfolio
- 12.7.5 Harmonic Pharma Recent Developments
- 12.8 GlycoMimetics
- 12.8.1 GlycoMimetics Company Information
- 12.8.2 GlycoMimetics Business Overview
- 12.8.3 GlycoMimetics Revenue in CXCR4 Antagonists Business (2021-2026)
- 12.8.4 GlycoMimetics CXCR4 Antagonists Product Portfolio
- 12.8.5 GlycoMimetics Recent Developments
- 12.9 BioLineRx
- 12.9.1 BioLineRx Company Information
- 12.9.2 BioLineRx Business Overview
- 12.9.3 BioLineRx Revenue in CXCR4 Antagonists Business (2021-2026)
- 12.9.4 BioLineRx CXCR4 Antagonists Product Portfolio
- 12.9.5 BioLineRx Recent Developments
- 12.10 Biokine Therapeutics
- 12.10.1 Biokine Therapeutics Company Information
- 12.10.2 Biokine Therapeutics Business Overview
- 12.10.3 Biokine Therapeutics Revenue in CXCR4 Antagonists Business (2021-2026)
- 12.10.4 Biokine Therapeutics CXCR4 Antagonists Product Portfolio
- 12.10.5 Biokine Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst